

FIRST PROSPECTUS SUPPLEMENT DATED 2 JUNE 2025
TO THE BASE PROSPECTUS DATED 28 APRIL 2025

EssilorLuxottica

€12,000,000,000

Euro Medium Term Note Programme

This first prospectus supplement (the "**First Prospectus Supplement**") is supplemental to, and should be read in conjunction with, the base prospectus dated 28 April 2025 which received approval number 25-122 (the "**Base Prospectus**") from the *Autorité des marchés financiers* (the "**AMF**") prepared in relation to the Euro Medium Term Note Programme (the "**Programme**") of EssilorLuxottica (the "**Issuer**"). The Base Prospectus constitutes a base prospectus for the purposes of article 8 of Regulation (EU) 2017/1129 of 14 June 2017, as amended (the "**Prospectus Regulation**").

Application has been made for approval of this First Prospectus Supplement to the AMF in its capacity as competent authority pursuant to the Prospectus Regulation.

This First Prospectus Supplement has been prepared pursuant to article 23(1) of the Prospectus Regulation, for the purposes of incorporating recent events relating to the Issuer.

Save as disclosed in this First Prospectus Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Base Prospectus which may affect the assessment of the Notes since the publication of the Base Prospectus.

Unless the context otherwise requires, terms defined in the Base Prospectus shall have the same meaning when used in this First Prospectus Supplement.

To the extent there is any inconsistency between (a) any statement in this First Prospectus Supplement and (b) any other statement in or incorporated by reference in the Base Prospectus, the statements in (a) above will prevail.

Copies of this First Prospectus Supplement will be available on the website of the Issuer (<https://www.essilorluxottica.com>) and on the website of the AMF (<https://www.amf-france.org>).

TABLE OF CONTENTS

| | |
|---|---|
| RECENT DEVELOPMENTS | 3 |
| PERSON RESPONSIBLE FOR THIS FIRST PROSPECTUS SUPPLEMENT | 7 |

RECENT DEVELOPMENTS

The following press releases published by the Issuer are included in a new section entitled "Recent Developments" inserted after section "Description of EssilorLuxottica" appearing on page 125 of the Base Prospectus:

EssilorLuxottica 2025 Annual Shareholders' Meeting

- **All resolutions proposed by the Board of Directors adopted**
- **Dividend of Euro 3.95 per share, with option for payment in shares**

Paris, France (30 April 2025 – 6:00 pm CEST) – EssilorLuxottica Annual Shareholders' Meeting was held today at 3 Mazarium in Paris. Shareholders approved all 17 resolutions submitted by the Board of Directors to the Ordinary and Extraordinary General Meeting, including the distribution of a Euro 3.95 dividend per share for the financial year 2024 and the compensation policy applicable to the Company's Executive Corporate Officers.

"We thank all our shareholders, including the nearly 100,000 employee shareholders, for their trust and support during a time of profound transformation for our Group. We are shaping EssilorLuxottica into a stronger leader in med-tech and wearable computing, building our growth strategy on an unmatched industrial and logistics platform in the optical industry and a unique portfolio of iconic brands. This strategy not only creates value for all – as reflected in today's approval of a Euro 3.95 dividend, nearly double the first one paid in 2018 – but also unlocks new opportunities for future growth and breakthrough innovation, which we look forward to sharing with all our stakeholders," commented Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO at EssilorLuxottica after the meeting.

Payment of the dividend and option for payment of the dividend in shares

The resolution granting shareholders the option to receive their final dividend to be paid for the financial year ended on December 31, 2024, in shares has also been approved. As duly acknowledged by the Board of Directors, the price for newly issued shares for the payment of the dividend has been set at Euro 222.02 per share.

- This price corresponds to 90% of the average of the opening prices on Euronext Paris during the twenty trading days preceding the date of the Annual General Meeting less the amount of the final dividend to be distributed for the financial year ended on December 31, 2024, this total being rounded up to the next euro cent.
- The ex-dividend date¹ is set on May 7, 2025. The record date² is set on May 8, 2025.

Shareholders will be entitled to opt for payment of the dividend in newly issued shares between May 9, 2025 and May 30, 2025, inclusive (except for shareholders holding shares in pure registered form who have to exercise such option on May 28, 2025 at the latest). To exercise such option, shareholders have to address their request to the authorized financial intermediaries. For shareholders holding shares in pure registered form, the request will have to be addressed to the Company's agent (Uptevia, 90 – 110 Esplanade du Général de Gaulle – 92931 Paris La Défense Cedex). For shareholders who have not exercised their option by the abovementioned deadlines,

the final dividend will be entirely paid in cash.

An application will be made to admit the new shares for trading on Euronext Paris market. The new ordinary shares allocated in payment will confer the same rights as the existing shares and carry current dividend rights (*“jouissance courante”*), i.e. they will confer the right to any distribution paid out as from the date of their issuance.

If the amount of the final dividend in respect of which the option will be exercised does not correspond to a whole number of shares, the shareholder will receive the number of shares rounded down to the nearest inferior whole number, and a balancing payment in cash (*“soulte”*).

The payment of the dividend or the delivery of the new shares following the exercise of the option will take place on June 5, 2025.

Shareholders may connect to www.essilorluxottica.com to consult the Questions & Answers dedicated to the payment of dividend in shares.

Forthcoming Shareholder Key Dates

- Ex date¹: May 7, 2025.
- Record date²: May 8, 2025
- Period to exercise the option: May 9, 2025 to May 30, 2025, inclusive
- Date of payment: June 5, 2025.

Webcast of the Annual Shareholders' Meeting

To access the replay webcast of the Annual General Meeting that will be made available at 6:30 pm CEST, please visit <https://www.essilorluxottica.com/annual-shareholders-meetings>

Notes

1 First date from which EssilorLuxottica shares are traded without the dividend rights.

2 Date on which positions are determined by the central securities depository at close of business.

* * *

EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy

Acquisition of leading ophthalmology platform from MidEuropa will advance the Group's development of the most comprehensive and digital-forward patient journey

Paris, France and London, United Kingdom (30 May 2025) – EssilorLuxottica and MidEuropa announced today they entered into an agreement for EssilorLuxottica to acquire Optegra, a fast-growing and highly integrated ophthalmology platform operating in five key European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands.

The acquisition represents a significant milestone in EssilorLuxottica's med-tech strategy, building on the Group's offering which today spans far beyond frames and lenses to include AI-powered innovative technologies, wearables, medical instruments and science-backed eyecare solutions that improve the lives of millions of people.

The Optegra group, under the Optegra, Lexum and Iris brands, operates an extensive network of over 70 eye hospitals and diagnostic facilities across Europe, offering medically necessary ophthalmic treatments and elective vision correction procedures supported by AI in pre- and post-op stages. These include sight-saving cataract surgery, age-related macular degeneration and glaucoma treatments, refractive lens replacement and laser eye surgery, serving both publicly reimbursed and private-pay patients. Since 2007, its highly ranked surgeons and dedicated medical teams have established a strong foundation of clinical leadership and a trusted reputation for quality care and industry-leading outcomes, making the Optegra platform a natural fit for EssilorLuxottica's expanding med-tech portfolio.

"With the acquisition of Optegra, we are stepping into a new frontier – one where comprehensive eyecare, advanced diagnostics, therapeutic interventions and surgical treatments come together in one seamless platform. We have the strategic assets to fuel this vision: an extensive distribution network with new clinical approaches, a smart eyewear offering with healthcare potential, and diagnostic capabilities that will be able to detect conditions ranging from neurodegenerative diseases to cardiovascular dysfunction. Optegra and its experienced doctors will bring new medical capabilities to our Group, enabling us to address patients' needs with the most advanced vision care technologies and treatments in one trusted system that will anchor our med-tech aspirations. Powered by our growing AI and big data capabilities, we will be able to broaden our impact and deliver the most personalized and seamless patient journey," commented Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer at EssilorLuxottica.

"Optegra's evolution under MidEuropa's ownership reflects our approach to supporting high-quality European healthcare platforms with strong growth potential. We partnered with Peter Byloos and his experienced leadership team to accelerate the company's organic expansion and successfully entered two new markets, the Netherlands and Slovakia. We supported the opening of new clinics in the UK and completed eight strategic add-on acquisitions across five countries. We are proud to have contributed to Optegra's digitalization, implementation of AI technologies, and broader mission to expand access to high-quality eye care. We would like to thank the management team and clinical staff for their dedication and ambition throughout this journey. We believe EssilorLuxottica is the ideal partner to lead Optegra into its next phase of growth and innovation, and we wish them every success as they build on the strong foundation we have helped create," commented Robert Knorr, Managing Partner at MidEuropa.

"Joining forces with EssilorLuxottica marks a transformative chapter for Optegra. Their global leadership

in vision care, combined with our clinical excellence and patient-centric approach, creates an innovative platform to redefine the paradigm of ophthalmic services. This partnership not only accelerates our growth potential but also enhances our ability to deliver advanced, digital and integrated eyecare solutions to all our patients. It also creates a significant opportunity for our clinical team, our staff and leadership to be part of a global and inspiring leader in vision care,” commented Dr. Peter Byloos, Chief Executive Officer of Optegra Eye Health Care.

The transaction is expected to close later in 2025 pending regulatory approvals and other customary closing conditions.

PERSON RESPONSIBLE FOR THIS FIRST PROSPECTUS SUPPLEMENT

On 2 June 2025.

The Issuer declares, to the best of its knowledge, that the information contained in this First Prospectus Supplement is in accordance with the facts and makes no omission likely to affect its import.

ESSILORLUXOTTICA

147, rue de Paris
94220, Charenton-le-Pont
France

Duly represented by:

Kayvan Dauvergne
Head of Legal
authorised signatory

pursuant to a power of attorney from Mr. Francesco Milleri, Chairman and Chief Executive Officer and a power of attorney from Alessandro Malagrino, both dated 30 May 2025



Autorité des marchés financiers

This First Prospectus Supplement has been approved on 2 June 2025 by the AMF, in its capacity as competent authority under Regulation (EU) 2017/1129.

The AMF has approved this First Prospectus Supplement after having verified that the information it contains is complete, coherent and comprehensible within the meaning of Regulation (EU) 2017/1129. This approval does not imply any verification of the accuracy of such information by the AMF.

This approval is not a favourable opinion on the Issuer and on the quality of the Notes. Investors should make their own assessment of the opportunity to invest in such Notes.

This First Prospectus Supplement has received approval number 25-188.